Table 1.
Characteristics of patients with colorectal cancer
| Non-ACO cohort |
ACO cohort |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All patients |
Propensity score-matched patients |
All patients |
Propensity score-matched patients |
|||||||||
| K hospital (n=234) | R hospital (n=446) | p-value | K hospital (n=234) | R hospital (n=446) | p-value | Surgery group (n=27) | TCT group (n=47) | p-value | Surgery group (n=23) | TCT group (n=23) | p-value | |
| Age (yr) | 69 (62-75) | 70 (62-77) | 0.54a) | 69 (62-75) | 67 (60-74) | 0.20a) | 70 (64-75) | 71 (63-79) | 0.60a) | 70 (64-74) | 72 (63-81) | 0.54a) |
| Sex | ||||||||||||
| Male | 148 (63.2) | 258 (57.8) | 0.17b) | 148 (63.2) | 147 (62.8) | 0.92b) | 19 (70.4) | 31 (66.0) | 0.70b) | 16 (69.6) | 16 (69.6) | > 0.99b) |
| Female | 86 (36.8) | 188 (42.2) | 86 (36.8) | 87 (37.2) | 8 (29.6) | 16 (34.0) | 7 (30.4) | 7 (30.4) | ||||
| Tumor location | ||||||||||||
| Rectum | 79 (33.8) | 122 (27.4) | 0.08b) | 79 (33.8) | 68 (29.1) | 0.27b) | 0 | 1 (2.1) | 0.64c) | 0 | 0 | > 0.99b) |
| Colon | 155 (66.2) | 324 (72.6) | 155 (66.2) | 166 (70.9) | 27 (100) | 46 (97.9) | 23 (100) | 23 (100) | ||||
| Stage | ||||||||||||
| II | 119 (50.9) | 226 (50.7) | 0.96b) | 119 (50.9) | 110 (47.0) | 0.41b) | 15 (55.6) | 26 (55.3) | 0.98b) | 11 (47.8) | 11 (47.8) | > 0.99b) |
| III | 115 (49.1) | 220 (49.3) | 115 (49.1) | 124 (53.0) | 12 (44.4) | 21 (44.7) | 12 (52.2) | 12 (52.2) | ||||
| R status | ||||||||||||
| R0 | 232 (99.1) | 432 (96.9) | 0.06b) | 232 (99.1) | 230 (98.3) | 0.69c) | 27 (100) | 44 (93.6) | 0.25c) | 23 (100) | 23 (100) | > 0.99b) |
| R1 | 2 (0.9) | 14 (3.1) | 2 (0.9) | 4 (1.7) | 0 | 3 (6.4) | 0 | 0 | ||||
| Adjuvant | ||||||||||||
| No | 82 (35.0) | 240 (53.8) | < 0.001b) | 82 (35.0) | 92 (39.3) | 0.34b) | 10 (37.0) | 26 (55.3) | 0.13b) | 9 (39.1) | 9 (39.1) | > 0.99b) |
| Yes | 152 (65.0) | 206 (46.2) | 152 (65.0) | 142 (60.7) | 17 (63.0) | 21 (44.7) | 14 (60.9) | 14 (60.9) | ||||
| Adjuvant regimen | ||||||||||||
| Oral fluoropyrimidine | 147 (96.7) | 195 (94.7) | 0.33b) | 147 (96.7) | 133 (93.7) | 0.22b) | 14 (82.4) | 18 (85.7) | > 0.99c) | 11 (78.6) | 13 (92.9) | 0.60c) |
| XELOX or FOLFOX | 5 (3.3) | 11 (5.3) | 5 (3.3) | 9 (6.3) | 3 (17.6) | 3 (14.3) | 3 (21.4) | 1 (7.1) | ||||
Values are presented as median (range) or number (%). ACO, acute colorectal obstruction; K hospital, Kasugai Municipal Hospital, Kasugai, Japan; R hospital, Nagoya Daini Red Cross Hospital, Nagoya, Japan; TCT, transanal colorectal tube; XELOX, oxaliplatin plus capecitabine; FOLFOX, oxaliplatin plus infusional 5-fluorouracil and leucovorin; IQR, interquartile range,
a)
Mann-Whitney U test,
b)
Chi-square test,
c)
Fisher exact probability test.